{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T17:43:33Z","timestamp":1794246213188,"version":"4.9.0"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Long-term real-world evidence beyond 24\u202fmonths for anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies is scarce, particularly regarding treatment persistence and planned discontinuation after goal attainment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a single-center retrospective study of consecutive patients aged \u226515 years who initiated galcanezumab or fremanezumab (monthly\/quarterly) between May 2021 and June 2022. Specifically, patients aged \u226515 years with episodic migraine (EM; &amp;lt;15 headache days\/month), high-frequency EM (HFEM; 8\u201314\u202fdays\/month), or chronic migraine (CM; \u226515\u202fdays\/month) were included according to the International Classification of Headache Disorders, 3rd edition (ICHD-3) criteria. The outcomes included monthly migraine days (MMDs), the Migraine Disability Assessment Scale (MIDAS), the Headache Impact Test (HIT-6), and the Visual Analogue Scale (VAS), which were assessed at baseline and at 1, 3, 6, 12, and 36\u202fmonths. Responder rates (RRs) (\u226550%, \u226575, and 100%) and continuation\/discontinuation reasons were summarized with prespecified and sensitivity analyses. The primary subgroup analysis was prespecified as EM vs. HFEM+CM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Overall, 50 patients were analyzed at baseline (mean age: 42.5\u202fyears; 88% women); 28 of the 50 (56%) patients continued therapy for 3\u202fyears. Among patients who continued therapy, MMDs decreased from 12.0\u202f\u00b1\u202f5.4 to 5.6\u202f\u00b1\u202f5.4 at 36\u202fmonths, with parallel improvements in the MIDAS, HIT-6, and VAS (all\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.01). Responder rates were durable (\u226550%: 55.6% at 36\u202fmonths; \u226575%: 29.6%; 100%: 11.1%). Discontinuation frequently reflected treatment completion after goal attainment (24%); no adverse-event\u2013related discontinuations occurred.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Over 3\u202fyears, anti-CGRP monoclonal antibodies provided sustained preventive effectiveness and favorable tolerability in routine practice, supporting individualized decision-making regarding continuation, planned discontinuation, and regimen selection.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2026.1827022","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T04:48:26Z","timestamp":1778647706000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Three-year real-world effectiveness, treatment persistence, and planned discontinuation of anti-calcitonin gene-related peptide monoclonal antibodies for migraine prevention: a single-center cohort from Japan"],"prefix":"10.3389","volume":"17","author":[{"given":"Hideyo","family":"Kasai","sequence":"first","affiliation":[{"name":"Department of Neurology, Showa Medical University School of Medicine","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taro","family":"Yasumoto","sequence":"additional","affiliation":[{"name":"Department of Neurology, Showa Medical University Fujigaoka Hospital","place":["Yokohama, Kanagawa, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shota","family":"Kosuge","sequence":"additional","affiliation":[{"name":"Department of Neurology, Showa Medical University School of Medicine","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Osanai","sequence":"additional","affiliation":[{"name":"Department of Neurology, Showa Medical University Fujigaoka Hospital","place":["Yokohama, Kanagawa, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keita","family":"Mizuma","sequence":"additional","affiliation":[{"name":"Department of Neurology, Showa Medical University School of Medicine","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinori","family":"Futamura","sequence":"additional","affiliation":[{"name":"Department of Neurology, Showa Medical University Fujigaoka Hospital","place":["Yokohama, Kanagawa, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kuroda","sequence":"additional","affiliation":[{"name":"Department of Neurology, Showa Medical University School of Medicine","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenjiro","family":"Ono","sequence":"additional","affiliation":[{"name":"Department of Neurology and Neurobiology of Aging, Graduate School of Medical Sciences, Kanazawa University","place":["Kanazawa, Ishikawa, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetomo","family":"Murakami","sequence":"additional","affiliation":[{"name":"Department of Neurology, Showa Medical University School of Medicine","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,13]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1001\/jamaneurol.2018.1212","article-title":"Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial","volume":"75","author":"Stauffer","year":"2018","journal-title":"JAMA Neurol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1177\/0333102418779543","article-title":"Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 phase 3 randomized controlled clinical trial","volume":"38","author":"Skljarevski","year":"2018","journal-title":"Cephalalgia"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"2515816320932573","DOI":"10.1177\/2515816320932573","article-title":"Efficacy and safety of galcanezumab for prevention of migraine headache in Japanese patients with episodic migraine: a phase 2 randomized controlled clinical trial","volume":"3","author":"Sakai","year":"2020","journal-title":"Cephalalgia Rep"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"e2211","DOI":"10.1212\/WNL.0000000000006640","article-title":"Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study","volume":"91","author":"Detke","year":"2018","journal-title":"Neurology"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1001\/jama.2018.4853","article-title":"Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial","volume":"319","author":"Dodick","year":"2018","journal-title":"JAMA"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa1709038","article-title":"Fremanezumab for the preventive treatment of chronic migraine","volume":"377","author":"Silberstein","year":"2017","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"033310242311776","DOI":"10.1177\/03331024231177649","article-title":"Effectiveness of three calcitonin gene-related peptide monoclonal antibodies for migraine: a 12-month, single-center, observational real-world study in Japan","volume":"43","author":"Suzuki","year":"2023","journal-title":"Cephalalgia"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1186\/s12883-022-03041-1","article-title":"Real-world evidence of galcanezumab for migraine treatment in Japan: a retrospective analysis","volume":"22","author":"Takizawa","year":"2022","journal-title":"BMC Neurol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/25158163231207322","article-title":"Evaluating the wearing-off effects of fremanezumab in high-frequency episodic migraine and chronic migraine: a real-world observational study in Japan","volume":"6","author":"Suzuki","year":"2023","journal-title":"Cephalalgia Rep"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/03331024251318016","article-title":"Guidelines of the international headache society for real-world evidence studies in migraine and cluster headache","volume":"45","author":"Pozo-Rosich","year":"2025","journal-title":"Cephalalgia"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","article-title":"The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"335","author":"von Elm","year":"2007","journal-title":"BMJ"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0333102417738202","article-title":"Headache classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition","volume":"38","author":"Arnold","year":"2018","journal-title":"Cephalalgia"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/head.14692","article-title":"Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: an American headache society position statement update","volume":"64","author":"Charles","year":"2024","journal-title":"Headache"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"39","DOI":"10.15082\/jsnt.41.1_39","article-title":"Assessment tools and outcomes in real-world migraine patients eligible for anti-CGRP antibody treatment","volume":"41","author":"Kasai","year":"2024","journal-title":"J Neurother"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1220285","DOI":"10.3389\/fneur.2023.1220285","article-title":"Real-world experience with monthly and quarterly dosing of fremanezumab for the treatment of patients with migraine in Japan","volume":"14","author":"Suzuki","year":"2023","journal-title":"Front Neurol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s10194-023-01636-8","article-title":"Persistence to anti-CGRP monoclonal antibodies and onabotulinumtoxinA among patients with migraine: a retrospective cohort study","volume":"24","author":"Charleston","year":"2023","journal-title":"J Headache Pain"},{"key":"ref17","first-page":"A60.1","article-title":"Real-world persistence and discontinuation of anti-CGRP monoclonal antibodies in migraine: 4-year follow-up results. Eur","volume":"33","author":"Mercadal-Orfila","year":"2026","journal-title":"J Hosp Pharm"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.3390\/jcm15051985","article-title":"Treatment persistence in migraine prophylaxis comparing CGRP monoclonal antibodies vs. high\u2212\/low-evidence conventional oral preventives-a comparative real-world evidence study of depersonalized data of the German pain e-registry","volume":"15","author":"\u00dcberall","year":"2026","journal-title":"J Clin Med"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.18553\/jmcp.2023.29.10.1119","article-title":"Real-world persistence and costs among patients with chronic migraine treated with onabotulinumtoxinA or calcitonin gene-related peptide monoclonal antibodies","volume":"29","author":"Schwedt","year":"2023","journal-title":"J Manag Care Spec Pharm"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1080\/17512433.2024.2417655","article-title":"Understanding the efficacy and tolerability of migraine treatment: a deep dive into CGRP antagonists","volume":"17","author":"Waliszewska-Pros\u00f3\u0142","year":"2024","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s10194-025-02256-0","article-title":"Decoding the long-term safety of anti-CGRP (receptor) mAbs: a meta-analysis and systematic review","volume":"27","author":"Hoehne","year":"2026","journal-title":"J Headache Pain"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1111\/j.1533-2500.2012.00530.x","article-title":"Adherence with migraine prophylaxis in clinical practice","volume":"12","author":"Berger","year":"2012","journal-title":"Pain Pract"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s13311-018-0621-8","article-title":"Current prophylactic medications for migraine and their potential mechanisms of action","volume":"15","author":"Sprenger","year":"2018","journal-title":"Neurotherapeutics"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1177\/0333102414547138","article-title":"Adherence to oral migraine-preventive medications among patients with chronic migraine","volume":"35","author":"Hepp","year":"2015","journal-title":"Cephalalgia"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1111\/head.12055","article-title":"Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II)","volume":"53","author":"Blumenfeld","year":"2013","journal-title":"Headache"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1016\/j.clinthera.2008.12.010","article-title":"Persistence with migraine prophylactic treatment and acute migraine medication utilization in the managed care setting","volume":"30","author":"Yaldo","year":"2008","journal-title":"Clin Ther"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1136\/jnnp-2023-333295","article-title":"Redefining migraine prevention: early treatment with anti-CGRP monoclonal antibodies enhances response in the real world (EUREkA study)","volume":"95","author":"Caronna","year":"2024","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1827022\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T04:48:41Z","timestamp":1778647721000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1827022\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,13]]},"references-count":27,"alternative-id":["10.3389\/fneur.2026.1827022"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2026.1827022","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.3389\/fneur.2026.1827022.s001","asserted-by":"subject"}]},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,13]]},"article-number":"1827022"}}